Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance

摘要

There is disclosed use of a composition comprising an exendin, or a compound derived therefrom, and a pharmaceutical carrier for the manufacture of a medicament for the treatment of impaired glucose tolerance in individuals who have not been diagnosed with diabetes mellitus, or to reduce the risk of a cardiovascular event or a cerebrovascular event associated with impaired glucose tolerance.